ReviewAnnual review of medicine2013
Reprogrammed cells for disease modeling and regenerative medicine.
Review in Annual review of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed.
- Direct Reprogramming of Human Fibroblasts into Fully Functional Trophoblast Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Recent progress in the identification and in vitro culture of skin organoids.Regenerative therapy · 2025Review
- An overview of stem cells and cell products involved in trauma injury.Regenerative therapy · 2025Review
- Chemically defined and growth factor-free system for highly efficient endoderm induction of human pluripotent stem cells.Stem cell reports · 2025Article
- Enhancing Gene Delivery in NB-4 Cells: Overcoming Transduction and Selection Challenges.Cells · 2024Article
- CHIR99021 and Brdu Are Critical in Chicken iPSC Reprogramming via Small-Molecule Screening.Genes · 2024Article
- Metabolic Quadrivalency in RSeT Human Embryonic Stem Cells.bioRxiv : the preprint server for biology · 2024Article
- Cloning by SCNT: Integrating Technical and Biology-Driven Advances.Methods in molecular biology (Clifton, N.J.) · 2023Article
- iPSCs-Based Therapy for Trabecular Meshwork.Handbook of experimental pharmacology · 2023Article
- Pramef12 enhances reprogramming into naïve iPS cells.Biochemistry and biophysics reports · 2022Article
- Neglected No More: Emerging Cellular Therapies in Traumatic Injury.Stem cell reviews and reports · 2021Review
- Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model.Stem cell reports · 2021Article
- In vivo partial reprogramming of myofibers promotes muscle regeneration by remodeling the stem cell niche.Nature communications · 2021Article
- Engineering Tissue-Informed Biomaterials to Advance Pulmonary Regenerative Medicine.Frontiers in medicine · 2021Article
- Differentiation of Human Induced Pluripotent Stem Cells (hiPSCs) into Osteoclasts.Bio-protocol · 2020Article
- Cellular reprogramming: Mathematics meets medicine.Wiley interdisciplinary reviews. Systems biology and medicine · 2020Review
- Role of Long Non-coding RNAs in Reprogramming to Induced Pluripotency.Genomics, proteomics & bioinformatics · 2020Review
- The Use of Induced Pluripotent Stem Cells as a Model for Developmental Eye Disorders.Frontiers in cellular neuroscience · 2020Article
- Endothelial Differentiation G Protein-Coupled Receptor 5 Plays an Important Role in Induction and Maintenance of Pluripotency.Stem cells (Dayton, Ohio) · 2019Article
- Human iPSC-derived trigeminal neurons lack constitutive TLR3-dependent immunity that protects cortical neurons from HSV-1 infection.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The conversion of somatic cells into pluripotent cells is transforming the way diseases are researched and treated. Induced pluripotent stem (iPS) cells' promise may soon be realized in the field of hematology, as hematopoietic stem cell transplants are already commonplace in clinics around the world. We provide a current comparison between induced pluripotent and embryonic stem cells, describe progress toward modeling hematological disorders using iPS cells, and illustrate the hurdles that must be overcome before iPS cell therapies will be available in clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.